Search results
Sex-dependent interactions between prodromal intestinal inflammation and LRRK2 G2019S in mice...
Nature· 13 hours agoProdromal gut inflammation exacerbates Parkinson’s disease endophenotypes in mouse carriers of human LRRK2 G2019S in a sex-dependent ...
Inhibikase halts plans for public offering of securities By Investing.com
Investing.com· 4 hours agoInhibikase Therapeutics, Inc. (NASDAQ:IKT), a biopharmaceutical company focused on developing ...
As Ozzy Osbourne announces stem cell therapy, experts urge caution, highlight risks
Fox News· 6 days ago"The thing is, you have it, and you go, ‘I don't feel that great,’ but I don't know what it would be...
Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA...
WTRF Wheeling· 5 days agoCapsida Biotherapeutics ("Capsida") today announced new preclinical data that demonstrate the potential of its next-generation intravenously (IV) administered gene therapy candidate, CAP-003 ...
UAB identifies a protein that could change the battle against Parkinson's disease
Hardwood Paroxysm· 4 days agoResearchers at the Autonomous University of Barcelona have found a therapeutic target to neutralize...
Eli Lilly’s and AstraZeneca’s Former Head of Research Dr. Jan Lundberg Elected as a New Board Member
Digital Journal· 7 hours agoNeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease
Neuralink Rival Backed By Jeff Bezos And Bill Gates Broadens Horizons With Plans To Treat Parkinson'...
Benzinga· 6 days agoWhat Happened: On Thursday at the Bloomberg Tech Summit, ...Oxley, disclosed the company’s expansion...
Experimental spinal cord implant helps Parkinson’s patient walk in new study
KEYT 3 Santa Barbara· 6 days agoFor Gauthier, 63, who has been living with Parkinson’s disease for almost three decades, these...
Health calendar for May 14, 2024
Florida Today via Yahoo News· 1 day agoCome and win prizes! Snacks provided. Tuesday, May 21, 10 a.m. to noon. RSVP or questions call 321-693-9246. Retain Your Brain: How to Age Proof Your...
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
Clinical Trials Arena via Yahoo Finance· 10 hours agoPhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase...
